The role of HPV testing in the follow-up of patients in different clinical scenarios after diagnosis of cervical preinvasive lesions and carcinomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10504560" target="_blank" >RIV/00064165:_____/25:10504560 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10504560

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oUVOrkVYFl" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oUVOrkVYFl</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14737140.2025.2573821" target="_blank" >10.1080/14737140.2025.2573821</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of HPV testing in the follow-up of patients in different clinical scenarios after diagnosis of cervical preinvasive lesions and carcinomas

Popis výsledku v původním jazyce

Introduction: Persistent human papillomavirus (HPV) infection is the causative factor for nearly all high-grade cervical lesions (CIN2/3) and invasive cervical cancers. HPV testing therefore plays a key role in the follow-up of patients treated surgically or managed conservatively. Areas covered: To optimize HPV testing in follow-up, we identified key clinical scenarios - conservative management of high-grade lesions, surveillance after conization or hysterectomy, post-surgical follow-up of cervical carcinoma, and monitoring after primary radiation therapy. We reviewed the evidence to propose a strategy for integrating HPV testing into follow-up. Expert opinion: HPV testing shows high sensitivity and nearly 100% negative predictive value after conization for cervical high-grade lesions. Post-surgical HPV status is a more reliable predictor of recurrence than histopathological margin assessment. A negative result identifies patients with very low relapse risk. However, the lifetime risk of recurrent dysplasia remains increased and mainly depends on HPV status. Conversely, after fertility-sparing surgery for T1b cervical cancer, HPV testing alone is insufficient to rule out all recurrences. Its role is also unclear in patients after hysterectomy for invasive cancer and in those whose preinvasive lesions regressed spontaneously.

Název v anglickém jazyce

The role of HPV testing in the follow-up of patients in different clinical scenarios after diagnosis of cervical preinvasive lesions and carcinomas

Popis výsledku anglicky

Introduction: Persistent human papillomavirus (HPV) infection is the causative factor for nearly all high-grade cervical lesions (CIN2/3) and invasive cervical cancers. HPV testing therefore plays a key role in the follow-up of patients treated surgically or managed conservatively. Areas covered: To optimize HPV testing in follow-up, we identified key clinical scenarios - conservative management of high-grade lesions, surveillance after conization or hysterectomy, post-surgical follow-up of cervical carcinoma, and monitoring after primary radiation therapy. We reviewed the evidence to propose a strategy for integrating HPV testing into follow-up. Expert opinion: HPV testing shows high sensitivity and nearly 100% negative predictive value after conization for cervical high-grade lesions. Post-surgical HPV status is a more reliable predictor of recurrence than histopathological margin assessment. A negative result identifies patients with very low relapse risk. However, the lifetime risk of recurrent dysplasia remains increased and mainly depends on HPV status. Conversely, after fertility-sparing surgery for T1b cervical cancer, HPV testing alone is insufficient to rule out all recurrences. Its role is also unclear in patients after hysterectomy for invasive cancer and in those whose preinvasive lesions regressed spontaneously.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Anticancer Therapy

ISSN

1473-7140

e-ISSN

1744-8328

Svazek periodika

25

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

1405-1413

Kód UT WoS článku

001597642500001

EID výsledku v databázi Scopus

2-s2.0-105019624736